Prevention of Cardiovascular Events by Antiplatelet Agents After Acute Coronary Syndrome
NCT01952392 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 4992
Last updated 2017-02-24
Summary
Prevention of cardiovascular events by antiplatelet agents after acute coronary syndrome
Conditions
- Acute Coronary Syndrome
Sponsors & Collaborators
- lead INDUSTRY
Eligibility
- Min Age
- 18 Years
- Max Age
- 130 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2013-10-31
- Primary Completion
- 2016-03-31
- Completion
- 2016-03-31
Countries
- France
Study Locations
More Related Trials
-
Ongoing WARfarin and Coronary STENTing
NCT00722319 ·Status: UNKNOWN
-
Residual Platelet Activity Despite Aspirin Utilization in Coronary Heart Disease
NCT01820429 ·Status: COMPLETED
-
Management of High Bleeding Risk Patients Post Bioresorbable Polymer Coated Stent Implantation With an Abbreviated Versus Prolonged DAPT Regimen
NCT03023020 ·Status: COMPLETED ·Phase: NA
-
Safety Study of Apixaban in Recent Acute Coronary Syndrome
NCT00313300 ·Status: COMPLETED ·Phase: PHASE2
-
Optimized Antiplatelet Therapy on the Prognosis of ACS Patients With Non-predominant Coronary Artery Disease After PCI
NCT04338919 ·Status: UNKNOWN ·Phase: NA
-
Antiplatelet Drug Resistances and Ischemic Events
NCT00501423 ·Status: COMPLETED
-
Coronary Artery Ectasia, Efficacy of Various Anti Thrombotic Regimens.
NCT05718531 ·Status: UNKNOWN ·Phase: PHASE3
-
Study on Safety and Effectiveness of Three Doses of Argatroban as Anticoagulant in Percutaneous Coronary Intervention (PCI)
NCT00508924 ·Status: COMPLETED ·Phase: PHASE2
-
Registry of the Combination of Antiplatelet Agents and Anticoagulant in Atrial Fibrillation Patients With a CHA2DS2VASc Score >1 Undergoing Percutaneous Coronary Interventions
NCT03012906 ·Status: UNKNOWN
-
A Study of Dalcetrapib in Patients Hospitalized For An Acute Coronary Syndrome (Dal-ACUTE)
NCT01323153 ·Status: COMPLETED ·Phase: PHASE3
-
Long-tErm Follow-uP of antithrombotIc Management Patterns In Acute CORonary Syndrome Patients in Asia
NCT01361386 ·Status: COMPLETED
-
START-Register: Survey on Anticoagulated Patients Register
NCT02219984 ·Status: RECRUITING
-
Platelet Reactivity and MES During CEA
NCT01547039 ·Status: UNKNOWN
-
Monitoring Response to Antiplatelet Therapy
NCT00327041 ·Status: UNKNOWN
-
Algorithm-based Tailoring of Dual Antiplatelet Therapy to Improve Outcomes Following Percutaneous Coronary Interventions
NCT05732701 ·Status: RECRUITING ·Phase: NA
-
Predictors of Cardiovascular Risk in Covid-19 Patients During Acute Disease and at Short Term Follow-up
NCT04371289 ·Status: COMPLETED
-
Platelet-Inhibitor Drug Trial in Coronary Angioplasty
NCT00000510 ·Status: COMPLETED ·Phase: PHASE3
-
Optimal Duration of Dual Antiplatelet Therapy After Drug-eluting Stent Implantation
NCT00822536 ·Status: COMPLETED ·Phase: PHASE4
-
A Pharmacokinetic Study Of SB-681323 In Subjects With Coronary Heart Disease Undergoing Percutaneous Intervention
NCT00291902 ·Status: COMPLETED ·Phase: PHASE2
-
Platelet Drug Trial in Coronary Disease Progression
NCT00000496 ·Status: COMPLETED ·Phase: PHASE3
-
Pretreatment of Acute Coronary Syndrome With Dual Antiplatelet Agents
NCT07039149 ·Status: RECRUITING
-
Triple or Dual Antithrombotic Therapy After PCI (TRIDUAL-PCI) Coronary Intervention in Patients With Non-valvular Atrial Fibrillation. Real-world Italian Multicenter Registry (TRIDUAL-PCI)
NCT04291287 ·Status: UNKNOWN
-
Pharmacodynamic Effects of Dabigatran in Patients on Dual Antiplatelet Therapy
NCT01852162 ·Status: COMPLETED ·Phase: NA
-
A Study to Compare the Safety of Rivaroxaban Versus Acetylsalicylic Acid in Addition to Either Clopidogrel or Ticagrelor Therapy in Participants With Acute Coronary Syndrome
NCT02293395 ·Status: COMPLETED ·Phase: PHASE2
-
A Study Evaluating the Associations Between Clinical Characteristics and Use of Oral Anticoagulants in Italian Elderly Participants With Non-Valvular Atrial Fibrillation
NCT05232643 ·Status: RECRUITING